关键事件时间线Key Event Timeline 2024–2026 Timeline
| 日期Date | 事件Event | 意义Significance |
|---|---|---|
| 2024-03 | FDA 批准 resmetirom (Rezdiffra) 治疗 MASHFDA approves resmetirom (Rezdiffra) for MASH | 首个 MASH 适应症药物First drug indicated for MASH |
| 2024-05 | FLOW 试验：semaglutide 显著降低 T2D+CKD 肾事件 24%FLOW trial: semaglutide significantly reduces renal events by 24% in T2D+CKD | GLP-1 RA 肾保护新证据New evidence for GLP-1 RA renal protection |
| 2024-12 | Tirzepatide 获批用于阻塞性睡眠呼吸暂停Tirzepatide approved for obstructive sleep apnea | 第三个非降糖适应症Third non-glycemic indication |
| 2025-06 | Vertex zimislecel ADA 数据：10/10 患者无需胰岛素Vertex zimislecel ADA data: 10/10 patients insulin-free | 干细胞治愈 T1D 概念验证Proof of concept for stem-cell cure of T1D |
| 2025-09 | Orforglipron 头对头优于司美格鲁肽降 A1COrforglipron superior to semaglutide for A1C in head-to-head | 口服 GLP-1 时代The oral GLP-1 era |
| 2025-12 | Wegovy 口服片获 FDA 批准；ADA 2026 标准发布Oral Wegovy tablet approved by FDA; ADA 2026 Standards released | — |
| 2026-03 | Retatrutide T2D III 期 TRIUMPH 数据公布Retatrutide T2D phase III TRIUMPH data released | 三激动剂可能 2027 获批Triple agonist may be approved in 2027 |
| 2026-04 | Orforglipron (Foundayo) 获 FDA 批准用于肥胖Orforglipron (Foundayo) approved by FDA for obesity | 首个口服小分子 GLP-1 RAFirst oral small-molecule GLP-1 RA |
1. 干细胞疗法 — Vertex Zimislecel (VX-880)1. Stem-cell therapy — Vertex Zimislecel (VX-880) Stem-cell Islet Therapy
2025 年 6 月美国糖尿病协会年会 (ADA Scientific Sessions)，Vertex 公布 FORWARD-101 (Phase 1/2/3) 试验的更新数据：
At the American Diabetes Association annual meeting (ADA Scientific Sessions) in June 2025, Vertex released updated data from the FORWARD-101 (Phase 1/2/3) trial:
- 12 名严重低血糖反复发作的 T1D 患者接受治疗
- 10 名接受全剂量者，1 年随访均无需外源性胰岛素
- 所有 12 人均恢复内源性 C-肽分泌（证实植入细胞活性）
- TIR > 90%；严重低血糖事件归零
- 需持续免疫抑制（防止异体排斥）
- 12 T1D patients with recurrent severe hypoglycemia were treated
- Of the 10 who received the full dose, all were free of exogenous insulin at one-year follow-up
- All 12 restored endogenous C-peptide secretion (confirming graft cell activity)
- TIR > 90%; severe hypoglycemic events reduced to zero
- Continuous immunosuppression required (to prevent allogeneic rejection)
Vertex 计划 2025 年完成约 50 例患者入组与给药，2026 年向 FDA / EMA / MHRA 提交注册申请。 这是"功能性治愈" T1D最接近的临床实现。
Vertex plans to complete enrollment and dosing of about 50 patients in 2025 and to file for registration with the FDA / EMA / MHRA in 2026. This is the closest clinical realization of a "functional cure" for T1D.
- 免疫抑制方案 (Zimislecel/VX-880)：需终身免疫抑制；适合严重低血糖 T1D
- 免疫保护胶囊 (VX-264, Sernova, ViaCyte)：无需免疫抑制；尚处早期临床； 移植细胞活性维持是挑战
- Vertex 正在并行推进基于 iPSC 的自体细胞路线
- Immunosuppression approach (Zimislecel/VX-880): requires lifelong immunosuppression; suited to T1D with severe hypoglycemia
- Immunoprotective encapsulation (VX-264, Sernova, ViaCyte): no immunosuppression needed; still in early clinical stages; maintaining transplanted-cell viability is a challenge
- Vertex is also advancing an iPSC-based autologous cell route in parallel
2. 三激动剂 — Retatrutide (Eli Lilly)2. Triple agonist — Retatrutide (Eli Lilly) GLP-1/GIP/Glucagon
Retatrutide (LY3437943) 是首个进入 III 期的 GLP-1/GIP/胰高血糖素三靶激动剂。 胰高血糖素受体激动可增加能量消耗与脂肪氧化，与 GLP-1/GIP 的食欲抑制和胰岛素效应协同。
Retatrutide (LY3437943) is the first GLP-1/GIP/glucagon triple-target agonist to reach phase III. Glucagon-receptor agonism increases energy expenditure and fat oxidation, acting synergistically with the appetite-suppressing and insulin effects of GLP-1/GIP.
关键 III 期数据（TRIUMPH 项目）Key phase III data (TRIUMPH program)
- TRIUMPH-1 (T2D)：40 周 HbA1c ↓ 1.7%–2.0%（剂量依赖）； 最高剂量组减重 16.8%（约 36.6 lbs）
- TRIUMPH-OBESITY：48 周减重达 24%–26%（无糖尿病人群中可能更高）
- 另有 6 项 III 期研究（CKD、MASH、HFpEF、CV outcomes）2026 年内陆续读出
- TRIUMPH-1 (T2D): HbA1c ↓ 1.7%–2.0% at 40 weeks (dose-dependent); 16.8% weight loss (about 36.6 lbs) in the highest-dose group
- TRIUMPH-OBESITY: up to 24%–26% weight loss at 48 weeks (possibly higher in non-diabetic populations)
- Six further phase III studies (CKD, MASH, HFpEF, CV outcomes) will read out through 2026
2026 BioSpace 报道指出，retatrutide 在最高剂量组出现某些 新的安全信号（具体细节正在分析中，包括心率小幅升高、潜在的肝酶变化等）。 FDA 审批时这将是关键审查点。
A 2026 BioSpace report noted that retatrutide showed certain new safety signals in the highest-dose group (specifics still under analysis, including a small heart-rate increase and potential changes in liver enzymes). This will be a key review point during FDA approval.
3. 口服 GLP-1 革命3. The oral GLP-1 revolution Oral GLP-1 Revolution
3.1 Orforglipron (Eli Lilly, Foundayo)3.1 Orforglipron (Eli Lilly, Foundayo)
第一个口服小分子 GLP-1 RA（非肽段），无需特殊吸收增强剂、不限制进食/饮水。 2026 年 4 月获 FDA 批准用于慢性体重管理。
The first oral small-molecule GLP-1 RA (non-peptide), requiring no special absorption enhancers and with no food/water restrictions. Approved by the FDA in April 2026 for chronic weight management.
- ATTAIN-1 (III 期肥胖)：减重 14.7%（平均 27.3 lbs）
- 2025-09 头对头研究：降 A1C 优于司美格鲁肽
- 2025-10 III 期 vs. 达格列净：orforglipron 优于 SGLT2i
- 预计 2026 Q2 全面商业化
- ATTAIN-1 (phase III obesity): 14.7% weight loss (average 27.3 lbs)
- 2025-09 head-to-head study: superior A1C reduction vs. semaglutide
- 2025-10 phase III vs. dapagliflozin: orforglipron superior to SGLT2i
- Full commercialization expected in Q2 2026
3.2 口服司美格鲁肽 (Wegovy 片剂)3.2 Oral semaglutide (Wegovy tablet)
原口服 Rybelsus (3/7/14 mg) 仅用于 T2D。2025 年 12 月 FDA 批准更高剂量的 Wegovy 口服片用于肥胖。
The original oral Rybelsus (3/7/14 mg) was for T2D only. In December 2025 the FDA approved a higher-dose oral Wegovy tablet for obesity.
肽段口服化的两大瓶颈是胃肠道降解与肠壁穿透性。 orforglipron 通过小分子模拟肽路线突破，意味着 GLP-1 类药物可大幅扩张可及性。 研发界正在跟进多个小分子 GLP-1 候选（如 danuglipron, 已停止；多家中国 biotech）。 另一条路线是 SNAC、肠溶包衣等吸收增强剂用于肽段。
The two major bottlenecks for oral peptides are gastrointestinal degradation and intestinal-wall permeability. Orforglipron broke through via a small-molecule peptide-mimetic route, meaning GLP-1 drugs can greatly expand accessibility. The field is following several small-molecule GLP-1 candidates (such as danuglipron, now discontinued; and multiple Chinese biotechs). Another route uses absorption enhancers such as SNAC and enteric coatings for peptides.
4. Teplizumab — T1D 疾病修饰治疗4. Teplizumab — disease-modifying therapy for T1D Anti-CD3 Immunotherapy
Teplizumab (Tzield) 于 2022 年 11 月获 FDA 批准，是首个延缓 T1D 进展的疾病修饰药物， 用于 Stage 2 T1D (≥ 8 岁) 患者。
Teplizumab (Tzield) was approved by the FDA in November 2022 as the first disease-modifying drug to delay T1D progression, for Stage 2 T1D patients (≥ 8 years).
关键证据Key evidence
- TN-10 试验：Stage 2 患者一疗程 (14 日 IV) 平均延迟进展至 Stage 3 约 2 年
- PROTECT 试验 (新发 T1D)：2 个疗程显著保留 C-肽
- Meta 分析 (n=834)：C-肽 AUC 在 6–24 个月随访中显著保留
- TN-10 trial: one course (14-day IV) in Stage 2 patients delayed progression to Stage 3 by an average of about 2 years
- PROTECT trial (new-onset T1D): 2 courses significantly preserved C-peptide
- Meta-analysis (n=834): C-peptide AUC significantly preserved over 6–24 months of follow-up
机制：Teplizumab 是抗 CD3 单抗，结合 CD3/TCR 复合体使自身反应性 T 细胞失能 (anergy)。
Mechanism: Teplizumab is an anti-CD3 monoclonal antibody that binds the CD3/TCR complex to render autoreactive T cells anergic.
未来 T1D 治疗可能是免疫调节 + β 细胞保护/再生的组合： ①Teplizumab + verapamil (Ca²⁺ 通道阻滞，保护 β 细胞，已有 II 期数据)； ②抗炎药 (如 IL-6 拮抗剂、JAK 抑制剂)； ③GLP-1 RA 改善 β 细胞应激； ④干细胞替代（晚期失代偿）。
Future T1D treatment may combine immunomodulation + β-cell protection/regeneration: ① Teplizumab + verapamil (Ca²⁺ channel blockade, β-cell protection, with phase II data); ② anti-inflammatory agents (such as IL-6 antagonists, JAK inhibitors); ③ GLP-1 RA to relieve β-cell stress; ④ stem-cell replacement (late-stage decompensation).
来源：Source: Wiley DMRR 2025 — Autoimmune T1D in the Era of DMT · Frontiers Endocrinol 2025 — Teplizumab Review
5. MASH/MASLD 治疗突破5. Breakthroughs in MASH/MASLD treatment Metabolic Liver Disease
大约 1/3 成人受 MASLD 影响，T2D 患者中达 50–70%。2024 年是 MASH 治疗里程碑年。
About 1/3 of adults are affected by MASLD, reaching 50–70% among T2D patients. 2024 was a milestone year for MASH treatment.
5.1 Resmetirom (Rezdiffra)5.1 Resmetirom (Rezdiffra)
口服选择性 THR-β 激动剂，2024 年成为 FDA 批准的首个 MASH 药物。 MAESTRO-NASH III 期：100 mg 组 MASH 缓解率 39%（合并使用 GLP-1 RA 时同样有效）。
An oral selective THR-β agonist that became the first FDA-approved MASH drug in 2024. MAESTRO-NASH phase III: 39% MASH resolution in the 100 mg group (equally effective when combined with a GLP-1 RA).
5.2 GLP-1 RA — Semaglutide for MASH5.2 GLP-1 RA — Semaglutide for MASH
2025 年 FDA 批准 司美格鲁肽 2.4 mg 用于 MASH。ESSENCE 等试验显示其改善炎症与纤维化。
In 2025 the FDA approved semaglutide 2.4 mg for MASH. Trials such as ESSENCE showed it improves inflammation and fibrosis.
5.3 双重/三重激动剂5.3 Dual/triple agonists
Tirzepatide (SYNERGY-NASH II 期：MASH 缓解 44–62%)、retatrutide、survodutide 均在 II 期显示对 MASLD 显著的肝脂肪与纤维化改善。
Tirzepatide (SYNERGY-NASH phase II: 44–62% MASH resolution), retatrutide, and survodutide all showed significant improvements in hepatic fat and fibrosis in MASLD in phase II.
6. AID 自动胰岛素输送6. AID — automated insulin delivery Automated Insulin Delivery
2026 ADA 标准首次将 AID 列为 所有 T1D 患者的首选，并取消多项准入门槛。
For the first time, the 2026 ADA Standards list AID as the first choice for all T1D patients and remove several access thresholds.
| 系统System | 算法Algorithm | 配套 CGMPaired CGM | TIR > 70% 患者比例Patients with TIR > 70% |
|---|---|---|---|
| MiniMed 780G | SmartGuard | Guardian 4 / Simplera | ≈ 78% |
| Tandem t:slim X2 / Control-IQ | Control-IQ | Dexcom G6/G7 | ≈ 75% |
| Omnipod 5 | SmartAdjust | Dexcom G6/G7, Libre 2 Plus | ≈ 73% |
| iLet Bionic Pancreas | iLet algorithm (autonomous) | Dexcom G6/G7 | ≈ 70% |
| Sequel twiist (2024 上市)(launched 2024) | Tidepool Loop | Dexcom G7 | — |
| Tandem MOBY (2026 加拿大)(2026 Canada) | Control-IQ+ | 移动 App 控制Mobile app control | — |
系统正向"无需餐前 bolus 输入"方向迭代（iLet 已尝试），与双激素泵 （胰岛素 + 胰高血糖素，Beta Bionics 等）共同代表下一代 AID 路线。
Systems are iterating toward "no pre-meal bolus input required" (iLet has already attempted this), which together with dual-hormone pumps (insulin + glucagon, Beta Bionics, etc.) represents the next-generation AID route.
7. 肠道菌群与代谢7. Gut microbiome and metabolism Microbiome Frontier
肠道菌群影响 GLP-1 分泌、胆汁酸代谢、炎症与药物效应：
The gut microbiome influences GLP-1 secretion, bile-acid metabolism, inflammation, and drug effects:
- 预测应答：Akkermansia muciniphila 与 Faecalibacterium prausnitzii 与 GLP-1 RA 应答相关， 可能作为预测疗效的菌群生物标志物
- GLP-1 RA 重塑菌群：多项研究证实司美/利拉鲁肽改变菌群组成，可能介导部分疗效
- 益生菌干预：L. paracasei LC-37 + B. animalis MN-Gup 可刺激内源性 GLP-1 分泌； 12 RCT Meta 分析显示益生菌降 HbA1c
- FMT：瘦人 FMT 可改善代谢综合征人群胰岛素敏感性
- 工程菌：重组 L. paracasei NFBC 338 表达长效 GLP-1 类似物（早期研究）
- Predicting response: Akkermansia muciniphila and Faecalibacterium prausnitzii correlate with GLP-1 RA response, potentially serving as microbial biomarkers for predicting efficacy
- GLP-1 RA reshapes the microbiome: multiple studies confirm semaglutide/liraglutide alter microbial composition, possibly mediating part of the efficacy
- Probiotic intervention: L. paracasei LC-37 + B. animalis MN-Gup can stimulate endogenous GLP-1 secretion; a 12-RCT meta-analysis showed probiotics lower HbA1c
- FMT: FMT from lean donors can improve insulin sensitivity in people with metabolic syndrome
- Engineered bacteria: recombinant L. paracasei NFBC 338 expresses a long-acting GLP-1 analog (early-stage research)
8. 指南更新汇总8. Summary of guideline updates Guidelines Updates
- ADA Standards of Care 2026 (Diabetes Care, Dec 2025)： CGM/AID 早期使用与扩大适应人群、GLP-1 用于 T1D + 肥胖、肥胖筛查纳入体脂指标、 营养指南强调地中海/低碳模式
- EASD 2025 Annual Meeting Highlights： 器官特异性获益（心、肾、肝）的多通路联合治疗；微生物组与精准营养
- WHO 妊娠期糖尿病首个全球指南 (2025)： 统一筛查与管理策略
- 中国 2 型糖尿病防治指南 2024 版： 首次将 GLP-1 RA 与 SGLT2i 推荐为合并 ASCVD/HF/CKD 的首选
- ADA Standards of Care 2026 (Diabetes Care, Dec 2025): early use and expanded eligibility for CGM/AID, GLP-1 for T1D + obesity, inclusion of body-fat metrics in obesity screening, nutrition guidance emphasizing Mediterranean/low-carbohydrate patterns
- EASD 2025 Annual Meeting Highlights: multi-pathway combination therapy for organ-specific benefits (heart, kidney, liver); microbiome and precision nutrition
- WHO's first global guideline on gestational diabetes (2025): unified screening and management strategies
- China type 2 diabetes prevention and treatment guideline, 2024 edition: for the first time recommends GLP-1 RA and SGLT2i as first choice in patients with comorbid ASCVD/HF/CKD